AI Engines For more Details: Perplexity Kagi Labs You
Contraception: Norgestimate, when combined with ethinyl estradiol, is primarily used as an oral contraceptive to prevent pregnancy. It works by inhibiting ovulation (the release of an egg from the ovary), thickening cervical mucus to impede sperm penetration, and altering the uterine lining to prevent implantation of a fertilized egg. This combination is available under various brand names such as Ortho Tri-Cyclen, Tri-Sprintec, and Trinessa.
Menstrual Disorders: Norgestimate-containing contraceptive pills may be prescribed to regulate menstrual cycles and treat menstrual disorders such as irregular or heavy menstrual bleeding (menorrhagia). By stabilizing hormonal fluctuations, norgestimate can help promote regular and lighter menstrual periods.
Acne: Norgestimate-containing oral contraceptives are sometimes prescribed to manage acne in women. They can help improve acne by reducing the levels of androgens (male hormones) in the body, which are known to contribute to the development of acne lesions.
Polycystic Ovary Syndrome (PCOS): Norgestimate-containing contraceptive pills may also be used off-label to manage symptoms of PCOS, a hormonal disorder characterized by irregular menstrual periods, excessive hair growth, acne, and infertility. By regulating menstrual cycles and reducing androgen levels, norgestimate can help improve symptoms of PCOS, although it is not specifically approved for this indication.
Premenstrual Syndrome (PMS): Some women may experience relief from symptoms of premenstrual syndrome, such as bloating, breast tenderness, and mood changes, while taking norgestimate-containing oral contraceptives. The hormonal balance provided by these contraceptives can help alleviate these symptoms in some individuals.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 5.2 | 0.9 | 4.78 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.2 | 0.55 |
| Allergies | 8.1 | 5 | 0.62 |
| Allergy to milk products | 1.8 | 1.6 | 0.13 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7 | 7.5 | -0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 0.7 | 3.29 |
| Ankylosing spondylitis | 4.2 | 1.2 | 2.5 |
| Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
| Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
| Asthma | 5.3 | 2.7 | 0.96 |
| Atherosclerosis | 1.9 | 2.8 | -0.47 |
| Atrial fibrillation | 3.8 | 2.8 | 0.36 |
| Autism | 11.3 | 9.4 | 0.2 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.4 | 1.4 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.8 | 0.3 | 1.67 |
| Cancer (General) | 0.6 | 3.3 | -4.5 |
| Carcinoma | 4.1 | 2.6 | 0.58 |
| Celiac Disease | 3.1 | 3.4 | -0.1 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 5.7 | 7 | -0.23 |
| Chronic Kidney Disease | 5.3 | 2.5 | 1.12 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 1.4 | 0.07 |
| Chronic Urticaria (Hives) | 1.5 | 1.5 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 8.6 | 2.8 | 2.07 |
| Constipation | 1.8 | 1.3 | 0.38 |
| Coronary artery disease | 2.6 | 3 | -0.15 |
| COVID-19 | 10 | 13 | -0.3 |
| Crohn's Disease | 8.4 | 5 | 0.68 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.8 | 1.4 | 1 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 11.4 | 10.4 | 0.1 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 3.1 | -0.55 |
| Endometriosis | 3.1 | 1.9 | 0.63 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.4 | 2.1 | 0.62 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 3.2 | 2.5 | 0.28 |
| Functional constipation / chronic idiopathic constipation | 6.2 | 5 | 0.24 |
| gallstone disease (gsd) | 3.9 | 1 | 2.9 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.9 | 0.67 |
| Generalized anxiety disorder | 2.8 | 2.7 | 0.04 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.3 | 1.2 | 0.92 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.8 | -1 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.8 | 1.3 | 1.92 |
| Heart Failure | 3.8 | 2 | 0.9 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 1.5 | 0.6 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.3 | 1.33 |
| hyperglycemia | 2.5 | 1.5 | 0.67 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.3 | 1.33 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.8 | 5.5 | -0.15 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 3.3 | 0.9 | 2.67 |
| IgA nephropathy (IgAN) | 1.6 | 4.8 | -2 |
| Inflammatory Bowel Disease | 9 | 9.9 | -0.1 |
| Insomnia | 2.7 | 2.5 | 0.08 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 8.3 | 5.4 | 0.54 |
| ischemic stroke | 3 | 1.7 | 0.76 |
| Liver Cirrhosis | 7.7 | 4.2 | 0.83 |
| Long COVID | 7.3 | 7.5 | -0.03 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.3 | 1.3 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.1 | -0.91 |
| ME/CFS without IBS | 1.8 | 2.1 | -0.17 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.2 | 0.7 | 2.14 |
| Metabolic Syndrome | 7.6 | 8.3 | -0.09 |
| Mood Disorders | 11.5 | 8.3 | 0.39 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 6.9 | 6.1 | 0.13 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.8 | 2.9 | -2.62 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5 | 5 | 0 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.6 | 1.67 |
| Obesity | 11.4 | 8.3 | 0.37 |
| obsessive-compulsive disorder | 6.3 | 4.5 | 0.4 |
| Osteoarthritis | 2.8 | 1.3 | 1.15 |
| Osteoporosis | 2.5 | 1.8 | 0.39 |
| pancreatic cancer | 1.5 | 0.6 | 1.5 |
| Parkinson's Disease | 9.1 | 6.9 | 0.32 |
| Polycystic ovary syndrome | 7.6 | 3.1 | 1.45 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.3 | -0.08 |
| Primary sclerosing cholangitis | 2.1 | 3.2 | -0.52 |
| Psoriasis | 3.3 | 3.6 | -0.09 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.9 | 4.4 | 0.8 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.3 | 2.9 | 1.52 |
| scoliosis | 0.5 | 0.3 | 0.67 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 1.6 | 1.8 | -0.13 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.7 | 1.14 |
| Stress / posttraumatic stress disorder | 2.6 | 2.8 | -0.08 |
| Systemic Lupus Erythematosus | 4.3 | 1.9 | 1.26 |
| Tic Disorder | 1.5 | 1.7 | -0.13 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 5.6 | 4.2 | 0.33 |
| Type 2 Diabetes | 9.2 | 8 | 0.15 |
| Ulcerative colitis | 5.8 | 7.7 | -0.33 |
| Unhealthy Ageing | 5.6 | 2.6 | 1.15 |
| Vitiligo | 2.2 | 1.7 | 0.29 |
